{"id":"eto","safety":{"commonSideEffects":[{"rate":"40–80","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"30–50","effect":"Nausea and vomiting"},{"rate":"20–40","effect":"Alopecia"},{"rate":"10–30","effect":"Mucositis"},{"rate":"1–5","effect":"Secondary malignancy (acute leukemia)"},{"rate":"1–3","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":{"setId":"03458123-e27c-4447-9ef3-3bd32481cb97","title":"ETODOLAC TABLET, FILM COATED [BRYANT RANCH PREPACK]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etoposide binds to the topoisomerase II–DNA complex and stabilizes the cleavage complex, preventing the religation of DNA strands. This results in accumulation of DNA double-strand breaks, particularly during S and G2 phases of the cell cycle, triggering apoptosis in rapidly dividing cells. It is commonly used in combination chemotherapy regimens for various malignancies.","oneSentence":"ETO (etoposide) is a topoisomerase II inhibitor that prevents DNA religation, leading to DNA strand breaks and cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:52:16.886Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer"},{"name":"Testicular cancer"},{"name":"Lymphomas"},{"name":"Leukemias"},{"name":"Sarcomas"}]},"trialDetails":[{"nctId":"NCT06744504","phase":"PHASE3","title":"Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-10","conditions":"AML, RUNX1-RUNX1T1 Fusion Protein Expression","enrollment":300},{"nctId":"NCT04701749","phase":"","title":"Study of the Effects of Anticoagulant Interruption Covered by Percutaneous Left Atrial Occlusion in Patients With Chronic Atrial Fibrillation and Radiation Cystitis at Risk of Bleeding","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2021-02-24","conditions":"Radiation Cystitis, Non-valvular Atrial Fibrillation","enrollment":40},{"nctId":"NCT03828565","phase":"NA","title":"Decrease of Post-operative Complications by SCVO2 Monitoring an Optimisation of Cardiac Flow","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-03-01","conditions":"Cardiac Flow","enrollment":220},{"nctId":"NCT07380425","phase":"NA","title":"Deep Breathing With and Without Pressure Support and PEEP for Preoxygenation in Obese Patients","status":"COMPLETED","sponsor":"Pamukkale University","startDate":"2021-12-01","conditions":"Obesity","enrollment":75},{"nctId":"NCT06395220","phase":"","title":"Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Haematological Malignancy","enrollment":314},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT07274488","phase":"NA","title":"The Effect of Preoxygenation on Gastric Decompression in Laparoscopic Cholecystectomies","status":"COMPLETED","sponsor":"Ankara City Hospital Bilkent","startDate":"2024-02-01","conditions":"Cholelithiasis","enrollment":128},{"nctId":"NCT05807399","phase":"PHASE2","title":"PanACEA - STEP2C -01","status":"RECRUITING","sponsor":"Michael Hoelscher","startDate":"2023-04-14","conditions":"Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis","enrollment":390},{"nctId":"NCT06499025","phase":"EARLY_PHASE1","title":"Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)","status":"ENROLLING_BY_INVITATION","sponsor":"BGI, China","startDate":"2024-02-01","conditions":"AML, t(8;21), Neoantigen","enrollment":16},{"nctId":"NCT05473195","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2022-12-06","conditions":"Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)","enrollment":105},{"nctId":"NCT05528588","phase":"PHASE2","title":"Furoscix in Heart Failure Patients With Diuretic Resistance","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-06-02","conditions":"Heart Failure","enrollment":70},{"nctId":"NCT06899867","phase":"","title":"Comparing Montiroing Cardiac Index by Transpulmonary Thermodilution and Transesophageal Echocardiography During Liver Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-11-27","conditions":"Liver Transplantation","enrollment":30},{"nctId":"NCT03686345","phase":"PHASE2","title":"Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia","status":"TERMINATED","sponsor":"Niguarda Hospital","startDate":"2018-07-01","conditions":"Core Binding Factor Acute Myeloid Leukemia (CBF-AML)","enrollment":34},{"nctId":"NCT06637800","phase":"NA","title":"Prospective, Open-label Study of Seraph 100 in Patients With Prolonged COVID (PC)","status":"NOT_YET_RECRUITING","sponsor":"ExThera Medical Corporation","startDate":"2025-02-15","conditions":"Long COVID","enrollment":100},{"nctId":"NCT06669013","phase":"PHASE3","title":"Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2021-05-20","conditions":"Bone Sarcoma, Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma","enrollment":40},{"nctId":"NCT02926586","phase":"PHASE4","title":"Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2017-01-01","conditions":"Acute Myeloid Leukemia, Core-Binding Factor","enrollment":68},{"nctId":"NCT06221683","phase":"PHASE2","title":"Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-01-01","conditions":"AML, Childhood, Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT03046732","phase":"NA","title":"Implementing \"Explore Transplant\"- A Pilot Study","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-11","conditions":"Endstage Kidney Disease","enrollment":227},{"nctId":"NCT02684708","phase":"PHASE3","title":"Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Giessen","startDate":"2015-10-01","conditions":"Classical Hodgkin Lymphoma","enrollment":2200},{"nctId":"NCT05504408","phase":"","title":"Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-09-01","conditions":"Systemic Mastocytosis With AHNMD, Acute Myeloid Leukemia With T(8;21)(Q22;Q22)","enrollment":200},{"nctId":"NCT02936089","phase":"NA","title":"Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-10","conditions":"Acute Myeloid Leukemia, Risk Stratification","enrollment":207},{"nctId":"NCT02727387","phase":"PHASE2","title":"Protocol for the Treatment of Metastatic Ewing Sarcoma","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2009-06-01","conditions":"Ewing's Sarcoma (ES)","enrollment":155},{"nctId":"NCT05520645","phase":"NA","title":"Etomidate Induction in Hysteroscopic Surgery","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-08-25","conditions":"Etomidate Induced Dose, Hysteroscopic Surgery","enrollment":200},{"nctId":"NCT03719183","phase":"","title":"Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-01-01","conditions":"Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT00462761","phase":"PHASE1","title":"A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-01","conditions":"Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome","enrollment":76},{"nctId":"NCT04311060","phase":"","title":"Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study.","status":"UNKNOWN","sponsor":"Mexican Agrupation for Hematology Study","startDate":"2020-03-22","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT01429610","phase":"PHASE2","title":"Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2011-11","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":78},{"nctId":"NCT02399007","phase":"NA","title":"A Clinical Trial Study of Hip System in Primary Total Hip Arthroplasty in China","status":"COMPLETED","sponsor":"Johnson & Johnson Medical (Suzhou) Ltd.","startDate":"2015-06-07","conditions":"Rheumatoid Arthritis, Congenital Hip Dysplasia, Avascular Necrosis","enrollment":160},{"nctId":"NCT02611648","phase":"NA","title":"Duodenoscope Disinfect Study","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2015-11","conditions":"Endoscopic Retrograde Cholangiopancreatogram (ERCP)","enrollment":541},{"nctId":"NCT00698672","phase":"NA","title":"RSA-Study of Cemented Hip Prostheses With Five Different Articulations","status":"UNKNOWN","sponsor":"Haukeland University Hospital","startDate":"2004-11","conditions":"Arthritis","enrollment":150},{"nctId":"NCT01776775","phase":"NA","title":"The Effect of Postoperative Abdominal Binder to Improve Outcomes After Incisional Hernia Repair","status":"WITHDRAWN","sponsor":"Hvidovre University Hospital","startDate":"2016-01","conditions":"Incisional Hernia","enrollment":""},{"nctId":"NCT01642121","phase":"","title":"Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2012-08","conditions":"Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia Without Maturation (M1)","enrollment":20},{"nctId":"NCT01673568","phase":"NA","title":"Abdominal Binder to Reduce Pain and Seroma Formation","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2012-10","conditions":"Ventral Hernias","enrollment":56},{"nctId":"NCT02024308","phase":"PHASE4","title":"AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2010-11","conditions":"Acute Myeloid Leukemia, AML1-ETO Fusion Protein Expression","enrollment":62},{"nctId":"NCT00792376","phase":"PHASE4","title":"\"NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes\"","status":"COMPLETED","sponsor":"Argentine Tennis Association","startDate":"2009-08","conditions":"Achilles Tendinopathy","enrollment":56},{"nctId":"NCT00946374","phase":"PHASE2","title":"Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2004-07","conditions":"Mantle-Cell Lymphoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2705,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Etoposide"],"phase":"marketed","status":"active","brandName":"ETO","genericName":"ETO","companyName":"Italian Sarcoma Group","companyId":"italian-sarcoma-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ETO (etoposide) is a topoisomerase II inhibitor that prevents DNA religation, leading to DNA strand breaks and cell death. Used for Small cell lung cancer, Testicular cancer, Lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}